𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Psoriasis predicts a poor short-term outcome in patients with spondylarthropathy

✍ Scribed by Stafford, L. ;Kane, D. ;Murphy, E. ;Duffy, T. ;Lassere, M. ;Youssef, P. P. ;Bresnihan, B. ;Fitzgerald, O.


Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
97 KB
Volume
45
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis


Objective. The outcome of patients with recent-onset spondylarthropathy (SpA) is unclear. Therefore, the objective of this study was to prospectively correlate clinical and laboratory features with functional and radiologic outcome in patients with psoriatic SpA (PsS), undifferentiated SpA (uSpA), and Reiter's syndrome/reactive arthritis (ReA). Methods. Patients presenting to an early arthritis clinic with a spondylarthropathy pattern of peripheral arthritis were selected and prospectively followed. Clinical and laboratory features were recorded at baseline, 12 months, and 24 months. Radiographs of affected joints were taken at presentation and at followup. Results. The cohort consisted of 157 patients: 82 PsS, 59 uSpA, and 16 ReA. Symptom duration at presentation was progressively shorter, and the erythrocyte sedimentation rate/C-reactive protein (ESR/CRP) incrementally higher in ReA, uSpA, and PsS, respectively. There was a higher swollen joint count (SJC) in PsS compared with uSpA. In PsS, strong positive correlations were observed between ESR/CRP and articular indices. Initially, functional impairment was greater in ReA compared with uSpA and PsS but resolved completely in ReA. Clinical remission rates at 2 years were ReA 61% and uSpA 63%, compared with PsS 14%. Remission at 2 years could be predicted in SpA by disease category and presentation SJC. Baseline erosions in PsS (28%) and uSpA (5%) increased to 45% and 25%, respectively, at 2 years. Conclusion. These observations suggest a spectrum within the spondylarthropathy subgroups where at presentation the acute phase markers in ReA and uSpA reflect a systemic process, whereas in PsS they reflect articular manifestations. Although the clinical presentations are indistinguishable, PsS has a more aggressive clinical course with a poorer functional and radiologic outcome.


πŸ“œ SIMILAR VOLUMES


Visible angiographic complications predi
✍ Paul Fefer; Amin Daoulah; Bradley H. Strauss; Robert Chisholm; John D. Sparkes; πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 189 KB

## Abstract Objectives: To assess whether visible angiographic complication is related to outcome in patients with elevated creatine phosphokinase (CK‐MB) following percutaneous coronary intervention (PCI). Background: Elevated biomarkers following PCI are associated with increased incidence of adv

Increased expression of galectin-1 in ca
✍ FrΓ©dΓ©ric A. van den BrΓ»le; David Waltregny; Vincent Castronovo πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 305 KB πŸ‘ 2 views

Galectin-1, a member of the beta-galactoside-binding galectin family, is a pleiotropic dimeric protein participating in a variety of normal and pathological processes, including cancer progression. Modulation of the interactions with the basement membrane glycoprotein laminin and induction of apopto

High levels of tissue inhibitor of metal
✍ Kevin McCarthy; Teresa Maguire; Gerald McGreal; Enda McDermott; Niall O'Higgins; πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 67 KB πŸ‘ 2 views

Studies from model systems suggest that matrix metalloproteinases (MMPs) are causally involved in tumor progression while tissue inhibitors of MMPs (TIMPs) prevent this progression. Here, we show that concentrations of TIMP-1 are significantly higher in breast carcinomas than in fibroadenomas. In pr

Predicting five-year outcome for patient
✍ Raymond L. Barnhill; Judith A. Fine; George C. Roush; Marianne Berwick πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 489 KB πŸ‘ 2 views

## BACKGROUND. In numerous studies tumor thickness has been shown to be the most important prognostic factor for patients with localized cutaneous melanoma. However, to our knowledge there are no population-based studies analyzing the prognosis of patients living in the United States with cutaneou